NCT06444113 - Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

May 18, 2026

Study Completion Date

February 23, 2027

Conditions

Multiple Sclerosis

Interventions

DRUG

Ofatunumab

No study-treatment is provided for this study. Study participants will be treated with commercially available ofatumumab according to the local label.

Trial Locations (22)

10126

RECRUITING

Novartis Investigative Site, Torino

22179

RECRUITING

Novartis Investigative Site, Hamburg

27110

RECRUITING

Duke Neurology, Durham

44791

RECRUITING

Novartis Investigative Site, Bochum

60190

RECRUITING

Northwestern Medicine Northwestern University, Winfield

71122

RECRUITING

Novartis Investigative Site, Foggia

72076

RECRUITING

Novartis Investigative Site, Tübingen

80045

RECRUITING

UC Health Neuroscience Ctr, Aurora

81377

RECRUITING

Novartis Investigative Site, Munich

94115

RECRUITING

UCSF, San Francisco

02445

RECRUITING

Brigham and Womens Hospital, Brookline

00133

RECRUITING

Novartis Investigative Site, Roma

15 276

RECRUITING

Novartis Investigative Site, Bialystok

25 726

RECRUITING

Novartis Investigative Site, Kielce

31 531

RECRUITING

Novartis Investigative Site, Krakow

35-323

RECRUITING

Novartis Investigative Site, Rzeszów

41-800

RECRUITING

Novartis Investigative Site, Zabrze

00968

RECRUITING

Caribbean Center for Clinical Research, Inc, Guaynabo

CB2 0QQ

RECRUITING

Novartis Investigative Site, Cambridge

NW1 2BU

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, London

OX3 9DU

RECRUITING

Novartis Investigative Site, Oxford

M6 8HD

RECRUITING

Novartis Investigative Site, Salford